References
- Einfeld, S. L., Piccinin, A. M., Mackinnon, A., Hofer, S. M., Taffe, J., Gray, K. M., … Tonge, B. J. (2006). Psychopathology in young people with intellectual disability. JAMA: The Journal of the American Medical Association, 296, 1981–1989. doi:10.1001/jama.296.16.1981
- Morris, C., Simkiss, D., Busk, M., Morris, M., Allard, A., Denness, J., … Cowan, K. (2015). Setting research priorities to improve the health of children and young people with neurodisability: A British Academy of Childhood Disability–James Lind Alliance Research Priority Setting Partnership. BMJ Open, 5, e006233. doi:10.1136/bmjopen-2014-006233
- Olfson, M., King, M., & Schoenbaum, M. (2015). Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry, 72, 867–874. doi:10.1001/jamapsychiatry.2015.0500
- Sheehan, R., Hassiotis, A., Walters, K., Osborn, D., Strydom, A., & Horsfall, L. (2015). Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ, 351, h4326.
- Symons, F. J., & Roberts, J. (2013). Biomarkers, behavior, and intellectual and developmental disabilities. American Journal on Intellectual and Developmental Disabilities, 118, 413–415. doi:10.1352/1944-7558-118.6.413
- Tomlinson, M., Yasamy, M. T., Emerson, E., Officer, A., Richler, D., & Saxena, S. (2014). Setting global research priorities for developmental disabilities, including intellectual disabilities and autism. Journal of Intellectual Disability Research, 58, 1121–1130. doi:10.1111/jir.2014.58.issue-12
- Tyrer, P., Oliver-Africano, P., Ahmed, Z., Bouras, N., Cooray, S., Deb, S., … Crawford, M. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomised controlled trial. The Lancet, 371, 57–63. doi:10.1016/S0140-6736(08)60072-0